Perseris Kit is owned by Indivior Inc.
Perseris Kit contains Risperidone.
Perseris Kit has a total of 9 drug patents out of which 0 drug patents have expired.
Perseris Kit was authorised for market use on 27 July, 2018.
Perseris Kit is available in for suspension, extended release;subcutaneous dosage forms.
Perseris Kit can be used as method of treating schizophrenia, treatment of schizophrenia, treating schizophrenia, administration of risperidone.
The generics of Perseris Kit are possible to be released after 13 February, 2028.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10406160 | INDIVIOR INC | Sustained release small molecule drug formulation |
Jun, 2026
(3 years from now) | |
US10058554 | INDIVIOR INC | Sustained release small molecule drug formulation |
Sep, 2026
(3 years from now) | |
US9597402 | INDIVIOR INC | Sustained release small molecule drug formulation |
Sep, 2026
(3 years from now) | |
US11110093 | INDIVIOR INC | Sustained release small molecule drug formulation |
Nov, 2026
(3 years from now) | |
US10010612 | INDIVIOR INC | Sustained delivery formulations of risperidone compounds |
Feb, 2028
(4 years from now) | |
US10376590 | INDIVIOR INC | Sustained delivery formulations of risperidone compound |
Feb, 2028
(4 years from now) | |
US9186413 | INDIVIOR INC | Sustained delivery formulations of risperidone compounds |
Feb, 2028
(4 years from now) | |
US9180197 | INDIVIOR INC | Sustained delivery formulations of risperidone compounds |
Feb, 2028
(4 years from now) | |
US11013809 | INDIVIOR INC | Sustained delivery formulations of risperidone compound |
Feb, 2028
(4 years from now) |
Drugs and Companies using RISPERIDONE ingredient
Market Authorisation Date: 27 July, 2018
Treatment: Method of treating schizophrenia; Administration of risperidone; Treating schizophrenia; Treatment of schizophrenia
Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS
17
United States
6
Japan
4
European Union
3
Spain
2
New Zealand
2
China
2
Canada
2
Mexico
2
Australia
2
Denmark
1
Poland
1
Hong Kong
1
Austria
1
Brazil
1
Israel
1
Taiwan
1
Argentina
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic